Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | OXTR | P30559 | 13/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781296 | 0.85 | OXTR (0.51) | ALDH1A1OXTRAVPR1AMAPKAPK2AVPR2 | |
| SCHEMBL6780224 | 0.83 | OXTR (0.51) | ALDH1A1OXTRAVPR1AMAPKAPK2AVPR2 | |
| SCHEMBL6780637 | 0.82 | LMNA (0.46) | ALDH1A1LMNATP53PDCD1CD274 | |
| SCHEMBL6774316 | 0.80 | ALDH1A1 (0.51) | ALDH1A1LMNATP53MAPKAPK2SNCA | |
| SCHEMBL6778658 | 0.80 | OXTR (0.46) | OXTRAVPR1AMAPKAPK2AVPR2 | |
| SCHEMBL6781601 | 0.77 | TP53 (0.64) | ALDH1A1LMNATP53 | |
| SCHEMBL6773967 | 0.77 | OXTR (0.53) | OXTRAVPR1AMAPKAPK2AVPR2 | |
| SCHEMBL23319565 | 0.70 | ERN1 (0.55) | ALDH1A1 | |
| SCHEMBL6778233 | 0.69 | HTT (0.51) | ALDH1A1LMNAPDCD1CD274 | |
| SCHEMBL6779695 | 0.69 | LMNA (0.49) | ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | claimed |
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | CETP, MTTP, LCAT | ALDH1A1 646/4885LMNA 4203/4885OXTR 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.